| | Variable | Yes (n = 117) | No (n = 213) | COR (95% CI) | AOR (95% CI) |
| | Age (years) | | | | | | 18-30 | 21 (17.9%) | 69 (32.7%) | 1.0 | 1.0 | | 31-40 | 34 (29.1%) | 93 (44.1%) | 1.2 (0.6,2.2) | 1.2 (0.6,2.8) | | 41-64 | 62 (53%) | 49 (23.2%) | 4.1 (2.2,7.6) | 3.1 (1.3,7.4) | | Educational status | | | | | | ≤Grade 8 | 82 (70.1%) | 66 (31.3%) | 6.9 (3.4,13.8) | 1.2 (0.5,3.3) | | Grade 9-12 | 23 (19.7%) | 78 (37.0%) | 1.6 (0.7,3.6) | 2.5 (0.9,6.6) | | Diploma and above | 12 (10.3%) | 67 (31.8%) | 1.0 | 1.0 | | Income (ETB/month) | | | | | | <500 | 41 (35.0%) | 27 (12.8%) | 5.6 (2.9,10) | 1.5 (0.53,4.0) | | 500-1000 | 43 (36.8%) | 54 (25.6%) | 2.9 (1.6,5.3) | 2.2 (0.9,5.1) | | 1001-1500 | 9 (7.7%) | 41 (19.4%) | 0.8 (0.3,1.9) | 0.5 (0.2,1.4) | | ≥1500 | 24 (20.5%) | 89 (42.2%) | 1.0 | 1.0 | | Lifetime khat chewing | | | | | | Yes | 75 (66.4%) | 75 (66.4%) | 8.1 (4.8,13.6) | 4.4 (2.3,8.3) | | No | 42 (19.5%) | 42 (19.5%) | 1.0 | 1.0 | | Comorbid hypertension | | | | | | Yes | 54 (46.2%) | 21 (10%) | 7.75 (4.3,13.8) | 2.2 (0.98,5.02) | | No | 63 (53.8%) | 190 (90%) | 1.0 | 1.0 | | Plasma HIV 1 RNA load (copies/ml) | | | | | | <1.7log10 | 35 (29.9%) | 139 (65.9%) | 1.0 | 1.0 | | 1.7log10-3log10 | 35 (29.9%) | 62 (29.4%) | 2.2 (1.3,3.9) | 2.2 (1.1,4.3) | | ≥3log10 | 47 (40.2%) | 10 (4.7%) | 18.6 (8.6,40.6) | 7.5 (2.6,21.5) | | Stage of the disease | | | | | | Stage I | 76 (65%) | 189 (89.6%) | 1.0 | 1.0 | | Stage II | 22 (18.8%) | 15 (7.1%) | 3.6 (1.79,7.4) | 0.9 (0.3,2.7) | | Stage III and above | 19 (16.2%) | 7 (3.3%) | 6.8 (2.7,16.7) | 5.6 (1.7,19.2) |
|
|
